Byondis

📣 This year's World ADC Conference will feature in-depth discussions of our innovative ADC platforms. Ronald Elgersma, PhD, Director of Protein & Medicinal Chemistry will be presenting our novel antifolate linker-drug platform, including its clinically validated antifolate MOA and its preclinical development across in vitro and in vivo studies. Mary van Helden, PhD, will highlight our phosphonate-ADC platform driving inside-out activation of Vγ9Vδ2 T Cells to selectively kill tumor cells and spotlighting an MHC-independent MoA, providing a promising solution to overcome resistance to checkpoint inhibitors with the opportunity to combine our linker-drug platform with any targeted moiety. ➡️ http://bit.ly/47hJWkS #WorldADC  #ADCInnovation  #AntibodyDrugConjugates  #OncologyResearch  #CancerResearch  #Oncology  #PhosphonateADC #AntifolateADC  #Byondis #MakeHopeReal

Thrilled to join the Business Development team at Byondis and I look forward to attending BioEurope next month in Vienna!   With fully integrated discovery, development and manufacturing capabilities, our goal is to rapidly advance our innovative platforms of novel immune-stimulating and cytotoxic payloads and tumor-specific masking technology to overcome resistances and increase the therapeutic index of new and established ADCs and novel formats. To realize the full potential of our science, pipeline, and technology, we are open to collaborations that will augment our ability to deliver meaningful solutions to patients as quickly as possible. I look forward to hearing from you, feel free to reach out to me on LinkedIn or here: [email protected] #BioEurope #ADCInnovation #AntibodyDrugConjugates #OncologyResearch #CancerResearch #Oncology #Byondis #MakeHopeReal

📣Our Chief Business Officer, Dr. Christoph Korpus, MBA, will be speaking at the 2025 BioCentury BayHelix China Healthcare Summit on October 23rd in Shanghai.    We look forward to sharing how Byondis is advancing our ByonGuardᵀᴹ masking, ByonBoostᵀᴹ and Antifolate Linker-Drug platforms to overcome current challenges in the ADC space.   Our lead programs combine these platforms to enable advanced targeting with optimized safety through masking and tumor-selective activation to deliver best-in-class therapeutics for unmet medical needs.   Learn more: http://bit.ly/48uLVVk    ➡️Reach out to our team: [email protected]    #BioCenturyChinaSummit  #ADCInnovation  #AntibodyDrugConjugates #OncologyResearch  #CancerResearch  #Oncology  #Byondis #MakeHopeReal 

📣 Byondis' Senior Scientist, Bioanalytics & DMPK, Myrthe Rouwette, is presenting on “Exploration of Mass Photometry as a Tool for the Characterization of Free Pharmacokinetic Assays” at the Refeyn user group meeting in Frankfurt. Mass photometry is emerging as a powerful technique to provide label-free, high-resolution insights into biomolecular interactions and Myrthe's work showcases its potential to enhance the development and optimization of pharmacokinetic assays critical to oncology drug development. ⭐ Pushing the boundaries of how we characterize complex biologics is vital to accelerating the next generation of antibody drug conjugates.  #Byondis #ADCInnovation #AntibodyDrugConjugates #OncologyResearch #CancerResearch #Oncology   

⭐ We’re thrilled to welcome our newest group of interns to Byondis! Our success is driven by results-oriented people with sharp minds and entrepreneurial spirits. Our interns will experience more than just a glimpse into the world of biotech, they'll have a hands-on opportunity to explore not only the road to drug development, but the many paths a biopharmaceutical career can take. We believe it’s essential to give students the space to put their knowledge into practice, for us all to learn from one another, and to grow alongside a team that values curiosity, impact, and collaboration. 🚀Welcome aboard Mila, Flora, Simon Wagener and Margo! #WeAreByondis #MakeHopeReal #OncologyResearch

⭐Bringing valuable experience, a shared passion for innovation, and a deep commitment to improving the lives of those affected by cancer, we're proud that our new colleagues joined the Byondis team and look forward to what we will accomplish together! Welcome to the team, Maarten Nieboer, Amanda Jeffries, Ron van Uden, Joran van den Heuvel, Carlien Kooijman - van den Brand, Edgard Marx and Diana Mittag! 🚀 #WeAreByondis #MakeHopeReal

📣 Bas Kokke, PhD, Principal Scientist of Downstream Processing, recently presented at the BioTalk Biological Manufacturing Excellence Conference in Berlin on "Investigations in virus filter process performance at different positions in the downstream process," a critical contribution to the development of innovative compounds like Byondis' work with (masked) mAbs and ADCs. His presentation focused on the exploration of virus filter process performance at different positions in the downstream process and found new virus filters enable the filtration of higher concentrated samples and placement further downstream in the purification process. The successful flexibility of the filters’ position demonstrated an effective removal of viruses irrespective of low or high flux viral clearance.    ➡️ Learn more about Byondis' pioneering scientific approach: https://bit.ly/46DizS1 #BioTalkEU #Byondis #ADCInnovation #OncologyResearch #AntibodyDrugConjugates #CancerResearch #Oncology #MakeHopeReal

📣 Byondis participated in the ADC Partnering & Investment Summit 2025 in Boston, where Dr. Christoph Korpus, MBA and Patrick Beusker, PhD, showcased how Byondis is driving innovation in antibody-drug conjugates, working to solve the toughest challenges in ADC development through pioneering linker-drug technologies, differentiated payload classes, and advanced antibody engineering.   Byondis’ fully integrated, in-house approach enables us to push the boundaries of ADC science, from discovery through manufacturing. Our next-generation platforms, including novel payloads, conditional masking, and immune-stimulating ADCs, are designed to improve precision, safety, and impact for patients worldwide.   Thank you to the ADC community for the inspiring discussions and collaboration. Together, we are shaping the future of cancer care.   #ADCInnovation #AntibodyDrugConjugates #CancerResearch #Oncology #Partnering #Byondis #MakeHopeReal

📣 Byondis participated in the ADC Partnering & Investment Summit 2025 in Boston, where Dr. Christoph Korpus, MBA and Patrick Beusker, PhD, showcased how Byondis is driving innovation in antibody-drug conjugates, working to solve the toughest challenges in ADC development through pioneering linker-drug technologies, differentiated payload classes, and advanced antibody engineering.   Byondis’ fully integrated, in-house approach enables us to push the boundaries of ADC science, from discovery through manufacturing. Our next-generation platforms, including novel payloads, conditional masking, and immune-stimulating ADCs, are designed to improve precision, safety, and impact for patients worldwide.   Thank you to the ADC community for the inspiring discussions and collaboration. Together, we are shaping the future of cancer care.   #ADCInnovation #AntibodyDrugConjugates #CancerResearch #Oncology #Partnering #Byondis #MakeHopeReal

Looking forward to connecting with colleagues at BioCentury Grand Rounds Europe in Cambridge, UK. Chief Business Officer, Dr. Christoph Korpus, MBA, will be presenting on Byondis’ diverse pipeline of proprietary next-generation ADCs and mAb therapeutics. Chief Scientific Officer, Wim Dokter, PhD, will be highlighting our innovative antifolate platform, bringing a clinically validated MoA into the ADC landscape with enhanced selectivity, potency, and manufacturability. 👉If you are interested in learning more or would like to connect, please reach out to: [email protected] #BioCenturyGrandRoundsEurope #ADCInnovation #Oncology #AntibodyDrugConjugates #Byondis #OncologyResearch #ClinicalTrials #MakeHopeReal